Cullinan Therapeutics (CGEM) investor group discloses 6,491,123-share position

Rhea-AI Filing Summary

Biotechnology Value Fund and affiliated entities report significant ownership of Cullinan Therapeutics, Inc. common stock. As of June 30, 2026, the group, including a managed account, beneficially owns 6,491,123 shares of common stock, representing approximately 9.99% of the outstanding shares.

The position includes 204,209 shares of Series A convertible preferred stock, which are convertible into 2,042,090 common shares at a 10:1 ratio. A 9.99% “Conversion Blocker” currently limits conversion to 740,440 of these underlying shares. Individual vehicles BVF and BVF2 hold approximately 5.7% and 3.5% of the class, respectively, with shared voting and dispositive power allocated among the BVF entities and Mark N. Lampert as described.

Key Figures

Aggregate preferred shares: 204,209 shares of Series A convertible preferred stock Underlying common shares: 2,042,090 shares of common stock Conversion ratio: 10 Shares per preferred share +5 more

8 metrics

Aggregate preferred shares 204,209 shares of Series A convertible preferred stock Held by BVF reporting persons and a managed account as of June 30, 2026

Underlying common shares 2,042,090 shares of common stock Total common shares issuable upon conversion of Series A preferred stock

Conversion ratio 10 Shares per preferred share Each Series A convertible preferred share converts into 10 common shares

Blocker-limited conversion 740,440 Shares Maximum common shares currently convertible due to the 9.99% Conversion Blocker

Group beneficial ownership 6,491,123 Shares Common shares beneficially owned in aggregate by BVF, BVF2, Trading Fund OS and a managed account

Group ownership percentage 9.99% Approximate percentage of Cullinan common stock beneficially owned by Partners, BVF Inc. and Mark N. Lampert

Shares outstanding baseline 61,458,046 Shares Common shares outstanding as of April 30, 2026 used in ownership calculations

Recent issuance to group 2,777,800 Shares Common shares issued to the reporting persons on June 26, 2026 upon conversion of preferred stock

Key Terms

Series A convertible preferred stock, Conversion Blocker, beneficially own, beneficially owned, +1 more

5 terms

Series A convertible preferred stock financial

"held an aggregate of 204,209 shares of Series A convertible preferred stock"

Series A convertible preferred stock is a class of shares sold in an early funding round that gives investors a mix of protection and upside: it pays a priority claim over common shares if the company is sold or closes, but can be converted into ordinary shares to share in future growth. Think of it like a hybrid between a safer stake and a ticket to ownership; it matters to investors because it affects who controls the company, how future gains are split, and how much their investment is protected from downside.

Conversion Blocker financial

"the holder will be prohibited from converting ... (the "Conversion Blocker")"

beneficially own financial

"would beneficially own a number of Shares above 9.99% of the total Shares"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

beneficially owned financial

"As of the close of business on June 30, 2026, (i) BVF beneficially owned 3,711,284 Shares"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

investment manager financial

"Partners, as the investment manager of BVF, BVF2 and Trading Fund OS"

FAQ

What ownership stake in Cullinan Therapeutics (CGEM) does Biotechnology Value Fund report?

Biotechnology Value Fund and affiliates report beneficial ownership of 6,491,123 Cullinan Therapeutics shares, or about 9.99% of the outstanding common stock. This total includes shares held by BVF, BVF2, a trading fund, and a Partners-managed account.

How many Cullinan Therapeutics (CGEM) preferred shares does the BVF group hold and what is the conversion rate?

The BVF group and a managed account hold 204,209 shares of Series A convertible preferred stock. Each preferred share is convertible into 10 common shares, for a total of 2,042,090 underlying Cullinan Therapeutics common shares, subject to a conversion limitation.

What is the 9.99% Conversion Blocker described for Cullinan Therapeutics (CGEM)?

The filing describes a 9.99% Conversion Blocker, which prevents holders from converting Series A preferred stock if it would lift their beneficial ownership above 9.99% of Cullinan’s outstanding common shares immediately after conversion.

How much of Cullinan Therapeutics (CGEM) stock does BVF beneficially own individually?

As of June 30, 2026, Biotechnology Value Fund, L.P. beneficially owns 3,711,284 Cullinan shares, or about 5.7% of the class. This includes 740,440 shares underlying Series A preferred stock and excludes an additional 374,620 underlying shares blocked from conversion.

What ownership percentage of Cullinan Therapeutics (CGEM) is attributed to BVF II and related entities?

BVF II, L.P. beneficially owns 2,269,166 Cullinan shares, or around 3.5% of the outstanding common stock. Through control relationships, BVF II GP and BVF GP Holdings may be deemed to beneficially own aggregate positions of 3.5% and 9.2%, respectively.

How many Cullinan Therapeutics (CGEM) shares were recently issued to the BVF group?

The filing notes that 2,777,800 Cullinan common shares were issued to the BVF reporting persons on June 26, 2026 upon conversion of certain Series A preferred stock, contributing to the group’s total reported beneficial ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:13 PM Accepted by SEC EDGAR 08/14/2026 - 04:06 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 8)

Cullinan Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

230031106

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 230031106

1

Names of Reporting Persons

BIOTECHNOLOGY VALUE FUND L P

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,711,284.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,711,284.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,711,284.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.7 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 230031106

1

Names of Reporting Persons

BVF I GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,711,284.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,711,284.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,711,284.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.7 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 230031106

1

Names of Reporting Persons

BIOTECHNOLOGY VALUE FUND II LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,269,166.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,269,166.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,269,166.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.5 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 230031106

1

Names of Reporting Persons

BVF II GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,269,166.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,269,166.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,269,166.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.5 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 230031106

1

Names of Reporting Persons

Biotechnology Value Trading Fund OS LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 400,861.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 400,861.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

400,861.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.6 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 230031106

1

Names of Reporting Persons

BVF Partners OS Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 400,861.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 400,861.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

400,861.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.6 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP Number(s): 230031106

1

Names of Reporting Persons

BVF GP HOLDINGS LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,980,450.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,980,450.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,980,450.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.2 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 230031106

1

Names of Reporting Persons

BVF PARTNERS L P/IL

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,491,123.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,491,123.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,491,123.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

CUSIP Number(s): 230031106

1

Names of Reporting Persons

BVF INC/IL

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,491,123.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,491,123.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,491,123.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP Number(s): 230031106

1

Names of Reporting Persons

LAMPERT MARK N

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,491,123.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,491,123.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,491,123.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Cullinan Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA 02142
Item 2.
(a)	Name of person filing: Biotechnology Value Fund, L.P. ("BVF") BVF I GP LLC ("BVF GP") Biotechnology Value Fund II, L.P. ("BVF2") BVF II GP LLC ("BVF2 GP") Biotechnology Value Trading Fund OS LP ("Trading Fund OS") BVF Partners OS Ltd. ("Partners OS") BVF GP Holdings LLC ("BVF GPH") BVF Partners L.P. ("Partners") BVF Inc. Mark N. Lampert ("Mr. Lampert") Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."
(b)	Address or principal business office or, if none, residence: Biotechnology Value Fund, L.P. 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF I GP LLC 44 Montgomery St., 40th Floor San Francisco, California 94104 Biotechnology Value Fund II, L.P. 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF II GP LLC 44 Montgomery St., 40th Floor San Francisco, California 94104 Biotechnology Value Trading Fund OS LP PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands BVF Partners OS Ltd. PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands BVF GP Holdings LLC 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF Partners L.P. 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF Inc. 44 Montgomery St., 40th Floor San Francisco, California 94104 Mark N. Lampert 44 Montgomery St., 40th Floor San Francisco, California 94104
(c)	Citizenship: Biotechnology Value Fund, L.P. Delaware BVF I GP LLC Delaware Biotechnology Value Fund II, L.P. Delaware BVF II GP LLC Delaware Biotechnology Value Trading Fund OS LP Cayman Islands BVF Partners OS Ltd. Cayman Islands BVF GP Holdings LLC Delaware BVF Partners L.P. Delaware BVF Inc. Delaware Mark N. Lampert United States
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 230031106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of the close of business on June 30, 2026, the Reporting Persons and a certain Partners managed account (the "Partners Managed Account") held an aggregate of 204,209 shares of Series A convertible preferred stock (the "Series A Preferred Stock"), convertible into an aggregate of 2,042,090 shares of the Issuer's Common Stock, par value $0.0001 per share (the "Shares"). Each share of Series A Preferred Stock is convertible into 10 Shares at the option of the holder at any time, subject to certain limitations, including that the holder will be prohibited from converting its Series A Preferred Stock into Shares if, as a result of such conversion, the holder, together with its affiliates, would beneficially own a number of Shares above 9.99% of the total Shares then issued and outstanding immediately following the conversion of such shares of Series A Preferred Stock (the "Conversion Blocker"). As of the close of business on June 30, 2026, the Conversion Blocker limits the conversion of the Series A Preferred Stock held by the Reporting Persons and the Partners Managed Account to 740,440 out of the 2,042,090 Shares underlying the Series A Preferred Stock held by them. As of the close of business on June 30, 2026, (i) BVF beneficially owned 3,711,284 Shares, including 740,440 Shares underlying certain Series A Preferred Stock held by it and excluding 374,620 Shares underlying certain Series A Preferred Stock held by it, (ii) BVF2 beneficially owned 2,269,166 Shares, excluding 807,180 Shares underlying the Series A Preferred Stock held by it, and (iii) Trading Fund OS beneficially owned 400,861 Shares, excluding 115,100 Shares underlying the Series A Preferred Stock held by it. BVF GP, as the general partner of BVF, may be deemed to beneficially own the 3,711,284 Shares beneficially owned by BVF. BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 2,269,166 Shares beneficially owned by BVF2. Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 400,861 Shares beneficially owned by Trading Fund OS. BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 5,980,450 Shares beneficially owned in the aggregate by BVF and BVF2. Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 6,491,123 Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, including 109,812 Shares held in the Partners Managed Account, which excludes 4,750 Shares underlying the Series A Preferred Stock held in the Partners Managed Account. BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 6,491,123 Shares beneficially owned by Partners. Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 6,491,123 Shares beneficially owned by BVF Inc. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.
(b)	Percent of class: The following percentages are based upon a denominator that is the sum of (i) 61,458,046 Shares outstanding as of April 30, 2026, which is the total number of Shares outstanding as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 7, 2026, (ii) 2,777,800 Shares issued to the Reporting Persons on June 26, 2026 upon the conversion of certain Series A Preferred Stock and (iii) 740,440 Shares underlying certain Series A Preferred Stock held by the Reporting Persons, as applicable. As of the close of business on June 30, 2026, (i) BVF beneficially owned approximately 5.7% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 3.5% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 5.7% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 3.5% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 9.2% of the outstanding Shares and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 9.99% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account).
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Cover Pages Items 5-9.
	(ii) Shared power to vote or to direct the vote: See Cover Pages Items 5-9.
	(iii) Sole power to dispose or to direct the disposition of: See Cover Pages Items 5-9.
	(iv) Shared power to dispose or to direct the disposition of: See Cover Pages Items 5-9.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. BVF GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF. BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF2. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by Trading Fund OS and held in the Partners Managed Account.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. See Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on November 8, 2021.
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BIOTECHNOLOGY VALUE FUND L P

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

BVF I GP LLC

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

BIOTECHNOLOGY VALUE FUND II LP

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

BVF II GP LLC

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

Biotechnology Value Trading Fund OS LP

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

BVF Partners OS Ltd.

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

BVF GP HOLDINGS LLC

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

BVF PARTNERS L P/IL

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

BVF INC/IL

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

LAMPERT MARK N

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert
Date:	08/14/2026